Discovery and Translational Sciences|Pneumonia & Pandemic Preparedness

Grant number: INV-034638

Grant search

Key facts

  • Disease

    COVID-19, Severe Acute Respiratory Syndrome (SARS)
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $1,037,250
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    United States of America
  • Lead Research Institution

    California Institute of Technology
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

to develop Pan-sarbecovirus vaccine strategies

Publicationslinked via Europe PMC

Last Updated:32 minutes ago

View all publications at Europe PMC

Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.

Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.